Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 92.94% is 167% above its 5-year average of 34.74%, near the high end of its 5-year range (-78.29%–100.00%).
2.85% above its 12-month average of 90.36%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
92.94%
GROSS MARGIN AVG TTM
90.36%
GROSS MARGIN AVG 3Y
56.13%
GROSS MARGIN AVG 5Y
34.74%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+2.85%
CURRENT VS 3Y AVG
+65.59%
CURRENT VS 5Y AVG
+167.49%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.63%
median of 726 covered companies
CURRENT VS SECTOR MEDIAN
+128.75%
vs the sector median at left
Monte Rosa Therapeutics, Inc.
Market Cap
$857.13M
Gross Margin
92.94%
TTM Avg
90.36%
3Y Avg
56.13%
5Y Avg
34.74%
Market Cap
$844.46M
Gross Margin
58.31%
TTM Avg
55.25%
3Y Avg
65.77%
5Y Avg
65.77%
Market Cap
$841.48M
Gross Margin
44.60%
TTM Avg
46.45%
3Y Avg
50.53%
5Y Avg
59.76%
Market Cap
$877.43M
Gross Margin
91.39%
TTM Avg
91.47%
3Y Avg
93.85%
5Y Avg
95.64%
Market Cap
$885.75M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$819.99M
Gross Margin
35.97%
TTM Avg
27.94%
3Y Avg
30.11%
5Y Avg
34.47%
Market Cap
$825.69M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | $857.13M | 92.94% | 90.36% | 56.13% | 34.74% |
| Beta Bionics, Inc. (BBNX)vs › | $844.46M | 58.31% | 55.25% | 65.77% | 65.77% |
| QuidelOrtho Corporation (QDEL)vs › | $841.48M | 44.60% | 46.45% | 50.53% | 59.76% |
| Alumis Inc. (ALMS)vs › | $839.96M | 88.23% | 42.73% | 21.36% | 21.36% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $877.43M | 91.39% | 91.47% | 93.85% | 95.64% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $885.75M | 0.00% | 0.00% | 0.00% | 0.00% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $819.99M | 35.97% | 27.94% | 30.11% | 34.47% |
| Jade Biosciences, Inc. (JBIO)vs › | $825.69M | 0.00% | 0.00% | 0.00% | 0.00% |
| Bioventus Inc. (BVS)vs › | $896.56M | 68.00% | 67.52% | 65.94% | 67.78% |
| Arbutus Biopharma Corp (ABUS)vs › | $896.82M | 99.98% | 98.71% | 99.36% | -14.89% |
Gross Margin
92.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 51.81% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | 100.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 56.12% |
| 2024-03-31 | -78.29% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
